07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , Mar 17, 2011 |  BC Innovations  |  Targets & Mechanisms

The hormone trigger in PTSD

Post-traumatic stress disorder is thought to involve changes in the circuitry of brain regions related to fear, although the specific molecular players have been elusive. Now, U.S. researchers have evidence that dysregulation of a brain...
08:00 , Mar 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Post-traumatic stress disorder (PTSD) Adenylate cyclase activating polypeptide pituitary (ADCYAP1; PACAP); adenylate cyclase activating polypeptide 1 pituitary...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology ...
08:00 , Jan 22, 2002 |  BC Week In Review  |  Company News

Complutense University other research news

Scientists reported in the Proceedings of the National Academy of Sciences evidence that PAC1 has an anti-inflammatory effect and increases survival in a mouse model of septic shock. PAC1-deficient mice had shorter survival times and...
08:00 , Nov 3, 1997 |  BC Week In Review  |  Company News

Kirin other research news

Kirin researchers and colleagues published in Nature Biotechnology the use of the pac1 ribonuclease gene from yeast to protect transgenic potato plants from infection by virus or viroid (circular single-stranded RNA virus-like particles). Ribonucleases such...